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ABSTRACT
Leishmaniasis is a worldwide tropical infectious disease caused by different species of 
intracellular protozoa parasites of the genus Leishmania. Herein, we report a 78-year-old 
man with unusual diffuse cutaneous leishmaniasis (DCL) who had a history of opium abuse 
and chronic obstructive pulmonary disease (COPD). He had multiple papular, crusted and 
severely ulcerated lesions extended to his arm and chest. Direct smears and skin punch biopsy 
of the lesions were suggestive of leishmaniasis. Parasite DNA was amplified from ulcers, 
and identified as Leishmania major by PCR-RFLP, confirmed by sequencing analyses. The 
aim of the current study was to bring to attention this atypical form of disease in CL endemic 
countries. Thus, this is the first case of DCL in an opium abuser with COPD due to L. major 
in Northeastern Iran indicating that atypical and extensive forms of CL (DCL) owing to L. 
major are increasing in Iran.
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INTRODUCTION 
Leishmaniasis, as a cosmopolitan infectious disease, is caused by protozoa 
parasites from the Kinetoplastida Leishmania spp., which are transmitted by the female 
sandfly and affects almost 12 million people worldwide1,2. The infection outcome 
varies according to the Leishmania species from severe cutaneous lesions to erosive 
mucosal ulcers with severe dermal disfigurements, to a life threatening visceral disease, 
depending directly on the interaction between parasites and the host immunity3,4. 
Iran is the main endemic focus of cutaneous leishmaniasis (CL)5,6 in the Middle 
East and the main etiological agents of CL in the country are three species : L. major, 
L. tropica and less frequently L. infantum1,5,7,8. Different forms of CL have been 
reported in Iran1 including post kala-azar dermal leishmaniasis (PKDL)9, muco-
lymphatic leishmaniasis10,11 and recently diffuse cutaneous leishmaniasis (DCL)12. 
DCL, a rare and unusual form of CL, is characterized by the absence of cellular 
immunity, high number of parasites inside host cells, uncontrolled progression of 
disease and no response to antileishmanial therapy.
This is the first report of an atypical case of DCL caused by L. major in an opium 
abuser with chronic obstructive pulmonary disease (COPD) in the Northeastern 
region of Iran who had a good response to antileishmanial therapy.
CASE REPORT
A 78-year-old male patient was referred to the Imam Reza Hospital, North 
This is an open-access article distributed under the 
terms of the Creative Commons Attribution License.
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Khorasan University of Medical Sciences, Bojnurd, Iran, 
for evaluation of disseminated skin lesions over the arm and 
hemithorax. As shown in Figure 1, he presented with one-
month history of multiple skin lesions, which started with a 
small furuncle on the left forelimb which progressed to other 
parts of the arm and hemithorax. He was originally resident 
in Esfarayen city in the Northeastern region of Iran, which is 
one of the new endemic regions of cutaneous leishmaniasis 
(CL). The patient declared that prior to the dissemination 
of the lesion, he had edema and lymphedema over the arm 
and hemithorax. Physical examination was remarkable for 
mild peripheral edema and lymphedema, but in radiological 
and laboratory tests, there were no abnormalities. At the 
time of physical examination, mild peripheral edema and 
lymphedema, but no systemic symptoms such as fever, 
hepatosplenomegaly were observed; however, he had 
a 10-year history of opium smoking abuse, as well as 
Chronic Obstructive Pulmonary Disease (COPD) which had 
previously been treated with Salbutamol (100 µg/4 times 
(puffs) per day) and Fluticasone/Salmeterol Spray (250/50 µg 
twice a day). The patient was hospitalized with an initial 
suspicion of diffuse bacterial infection due to lymphedema, 
opium smoking and history of respiratory disease. Physical 
examination showed that he had multiple, disseminated 
and wet-looking skin lesions which were papular, crusted 
and severely ulcerated all over the left arm and hemithorax 
(Figure 1). Furthermore, the patient’s lesions spread to his 
palm and all over the left finger nails which are very rare 
manifestations. It should be noted that three days before 
referring to the hospital, the patient bandaged up the lesions 
with plastic covers; therefore, all covered parts turned into 
creamy, wet-looking and severely inflammatory lesions 
which looked like second-degree burn wounds.
A hypothesis of leishmaniasis was made, and further 
evaluation by direct examination of the skin of the wrist 
and forearm using lesion scraping by a vaccinostyle, 
under sterile conditions was performed (Giemsa staining) 
revealing abundant intracellular Leishmania amastigotes 
inside and outside host cells (3+ parasitemia grade: 1–10 
parasites/microscopic field) (Figure 2A). In addition, for 
histopathological examination, punch biopsy of lesions of 
the wrist and forearm were performed (Hematoxylin and 
Eosin staining: H&E). Histopathological smears of wrist 
and forearm skin lesions revealed mild hyperkeratotic 
epidermis based on dermis infiltrated by numerous mixed 
inflammatory cells including abundant macrophages 
at dermis filled with amastigote forms of Leishmania 
(Figure 2B). Direct microscopy skin smears for acid-fast 
bacilli were negative. According to positive Giemsa-stained 
slide and skin biopsy, diagnosis of diffuse cutaneous 
leishmaniasis (DCL) was made Bone marrow aspiration 
showed no detectable Leishmania parasites among 
Figure 1 - Atypical disseminated cutaneous leishmaniasis 
(DCL) caused by Leishmania major in a patient with opium 
abuse and chronic obstructive pulmonary disease before 
antileishmanial therapy. The patient had multiple papular, 
crusted, severely ulcerated and creamy, wet-looking lesions 
that spread to his left arm and chest
Figure 2 - A) Abundant intracellular amastigote forms of Leishmania major (arrows) in the Giemsa-stained smear; B) in the skin 
biopsy stained with Hematoxylin and Eosin, prepared from an ulcerated area of the left wrist and forearm of the patient with 
disseminated cutaneous lesions (original magnification: ×1,000)
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myelogenous elements. All routine laboratory tests of 
the patient were normal. Viral markers (HIVAb, HBSAg, 
HCVAb), and anti-Brucella Ab (Wright, Coombs Wright and 
2-mercaptoethanol) were negative. In addition, serous fluid 
from the patient’s skin lesion were cultured in Schneider’s 
Drosophila medium (Sigma, Darmstadt, Germany), 
supplemented with 5% heat-inactivated fetal bovine serum 
(HI-FBS) (Sigma, Germany). Isolated parasites were 
subcultured and monitored regularly to check promastigotes 
growth. In this experiment, 2 × 106 parasites/mL 
at the logarithmic (2 days) growth phases were counted and 
used for DNA extraction.
Total genomic DNA of Leishmania parasites was 
extracted from cultured parasites and also from paraffin-
embedded blocks of the patient’s skin biopsy using the 
GF-1 DNA extraction kit (GF-1, Vivantis, Canada), and 
Leishmania ITS1 was amplified by polymerase chain 
reaction (PCR). For identification of Leishmania species 
by PCR-RFLP, the PCR product was digested using HaeIII 
(BsuRI) enzyme5,13; L. major parasites were identified as 
the causative agents of DCL. 
The patient’s first PCR product was subjected to 
sequence analysis using the forward and reverse primers 
according to the manufacturer’s instructions (Bioneer, South 
Korea). GenBank was searched for similar sequences and 
a significant similarity was found with other Leishmania 
species. The patient’s ITS1 sequence was similar to the 
Iranian strain of L. major (AB04/HU64) (99%).
The patient was initially treated with a bilayer wet 
dressing that was coated with silver sulfadiazine and 
petroleum salve/ointment along with vancomycin (1 g/kg/per 
12 h) and ceftriaxone (1 g/kg/per 12 h) as broad spectrum 
antibiotics. At the same time, he received antileishmanial 
therapy including: meglumine antimoniate (Glucantime) 
20 mg/kg/day for 10 days. Since he showed no significant 
improvement with Glucantime and developed pancytopenia 
as a complication of therapy, his treatment was discontinued 
at day 10. Consequently, he was placed on amphotericin B 
(3 mg/kg/per day for 10 days) and showed progressive and 
marked improvement of cutaneous lesions (Figure 3). 
During hospitalization and successful treatment, 
he developed a severe lung infection and disseminated 
bronchiectasis probably due to his history of opium 
abuse and COPD; therefore, he was admitted to ICU 
and unfortunately died because of a systemic bacterial 
superinfection. 
DISCUSSION
This is an unusual report of DCL caused by L. major 
in the Northeastern region of Iran in a patient with 
10 years history of opium abuse and respiratory disorder. 
He presented with an atypical form of CL with multiple, 
disseminated and creamy wet-looking skin lesions, which 
were papular, crusted and severally ulcerated all over the 
left arm and hemithorax.
DCL has been described in many countries, with a 
significant increase in the number of severe cases in highly 
endemic areas in the New World, and more recently in the 
Old World. It is characterized by an initial injury of the 
superficial and then the deep dermis followed by a high 
number of cutaneous polymorphic lesions with distinct 
features in the patient’s body surface, with or without 
mucosal involvement and usually having no effective 
response to treatment14,15. 
In the current case, the patient who was suffering from 
severe DCL described the initial appearance of a single 
furuncle exactly on the sand fly bite site of his left hand. 
Figure 3 - Patient with atypical disseminated cutaneous 
leishmaniasis (DCL) showing good response to treatment with 
amphotericin B and regression of his cutaneous lesions
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Few months later, due to opium abuse and COPD, the 
patient’s immune system was reduced; therefore, parasites 
could disseminate to other parts and lesions spread to the 
entire remote surface of the left arm and hemithorax, turning 
into disfiguring and extensive lesions within a few weeks. 
Pathogenesis of Leishmania infection depends 
directly upon the interaction between host cells and 
the Leishmania parasite involving immunological 
mechanisms16. Nevertheless, in DCL, situations are very 
different and the exact immunopathogenesis has not been 
well established so far. DCL has been characterized in 
several underlying conditions such as malignant diseases, 
organ transplantation, HIV positive patients, and importantly 
in opium abusers, due to diminished immune responses17,18. 
Some authors have shown that DCL is associated with a 
defective cellular immunity to Leishmania genus, parasites 
allowing their uncontrolled replication within host cells. In 
our DCL case, the patient was an opium smoking abuser 
which led to COPD; however, the association of opiates, 
infection, and their mechanism of action, are complex and 
multifactorial18. Opium as a narcotic drug is more prevalent 
in different parts of Iran, especially in Northeastern areas19. 
In chronic abusers of narcotics as in our case, the replication 
of T lymphocytes diminished significantly, so that exposure 
of host macrophages cells to opiates significantly reduced 
the production of distinct T-helper 1 (Th1) cytokines by a 
downregulation of their coding genes20. Briefly, the cell 
mediated immunity (Th1) responses deviate into humoral 
immunity (Th2) via the cAMP dependent pathway, which 
eventually blocks Th1 cytokines expression such as TNF-α, 
IFN-γ, IL-10 and IL-5, raising Th2 cytokines expression19,20. 
Therefore, lower expressions of the Th1 cytokines 
cause the dissemination of the Leishmania parasites14,21. 
Moreover, some studies showed that alkaloid opioids 
induce immunosuppression and depress the cell function of 
natural killer (NK) and phagocytic cells; therefore causing 
dissemination of parasites to other parts on body19,22.
Although in the current study, L. major was identified 
as the causative species of DCL which is the most 
frequent species associated with CL in Iran, it has been 
rarely reported as the causative agent of DCL in both, 
immunosuppressed and non-immunosuppressed patients. 
The most frequently described agents of DCL in the country 
are L. tropica and L. infantum17. 
Most cases of the DCL in Iran were reported in 
immunocompromised individuals such as HIV/AIDS 
patients; however, rare cases of the disease were described 
in patients with no immunosuppressive disorders17. In 
a study in Iran, Hajjaran et al.12 reported four cases of 
DCL with no immunossupression history in their medical 
notes and they did not respond to antileishmanial drugs. 
These authors suggested a potential role of Leishmania 
spp. genome characteristics for causing DCL in healthy 
patients. Therefore, we should not undervalue the 
potential of parasites genomes and their virulent hybrids 
in the dissemination of parasites to other parts of the 
body surfaces12. It seems that the number of DCL cases 
in patients with and without immunosuppression in Iran is 
rapidly increasing.
Although it may be considered that there several 
limitations in the current study, further investigation must 
be conducted in all endemic parts of Iran to follow up the 
patients with atypical forms of CL such as DCL, and the 
parasites should be sequenced to identify the Leishmania 
strains in the country.
CONCLUSIONS
Although there has been a rise in the number of DCL 
cases in recent decades in Iran, this is a rare case report of 
DCL in a patient with history of opium abuse and COPD, 
parameters that have been poorly described in the literature. 
The precise identification of DCL causative species by 
molecular techniques is vital for prevention, treatment and 
control of the disease and also for epidemiological studies. 
It is possible that some DCL cases have been missed as a 
result of the poor reporting system and lack of diagnostic 
facilities; therefore, it is highly suggested that health 
workers and physicians are educated to ensure correct 
diagnosis and management of atypical and rare CL forms 
in both immunosuppressed and non-immunosuppressed 
patients. Moreover, we strongly suggest the use of molecular 
techniques for identification of Leishmania spp. and the 
epidemiology of these parasites in all parts of the country 
and differentiation of DCL from other forms of cutaneous 
lesions.
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